Health insurance giant Humana Inc. (NYSE: HUM) stock initially rose in reaction to its fourth quarter of 2024 earnings report ...

CVS Health (CVS) has made an impressive comeback in 2025, with its stock soaring 45% so far this year. This sharp rebound ...

CVS is fighting to protect its PBM business as Trump and Congress look for ways to take out the pharmacy "middlemen." ...

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced Karen S. Lynch has been elected to its board of directors, effective February 19, 2025. The appointment ...

The Prescription Drug Affordability Act would aim to stop pharmacy benefit managers, or PBMs, from “exploiting loopholes” to ...

The appointment marks the latest in a spate of leadership changes at CVS as the company’s insurance segment struggles to ...

In the latest executive shakeup at CVS, the pharmacy giant has named a new president of its pharmacy benefit management ...

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

Argus raised the firm’s price target on CVS Health (CVS) to $77 from $68 and keeps a Buy rating on the shares. Despite an uneven performance ...

Earnings have fallen but are still strong enough to meet CVS Health's dividend commitment. Management expects adjusted earnings for 2025 to land in a range between $5.75 and $6 per share. That's ...

We recently compiled a list of the 10 Best Performing S&P 500 Stocks So Far in 2025. In this article, we are going to take a ...